Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LSS | P48449 | 12/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | ACHE | P22303 | 2/20 | 0.38 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.34 |
| ▸ | EZH2 | Q15910 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | BCHE | P06276 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | AR | P10275 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3669501 | 1.00 | LSS (0.46) | LSSKMT2AMEN1ACHECYP11B1 | |
| SCHEMBL3676960 | 0.83 | LSS (0.52) | LSSKMT2AMEN1ACHEALDH1A1 | |
| SCHEMBL3676963 | 0.83 | LSS (0.52) | LSSKMT2AMEN1ACHEALDH1A1 | |
| SCHEMBL8035588 | 0.81 | EZH2 (0.35) | KMT2AMEN1ACHEEZH2LMNA | |
| SCHEMBL7687539 | 0.80 | LSS (0.53) | LSSKMT2AMEN1ACHEALDH1A1 | |
| SCHEMBL7687535 | 0.80 | LSS (0.53) | LSSKMT2AMEN1ACHEALDH1A1 | |
| SCHEMBL3700933 | 0.80 | LSS (0.71) | LSSKMT2AMEN1 | |
| SCHEMBL7684578 | 0.80 | LSS (0.71) | LSSKMT2AMEN1 | |
| SCHEMBL7687514 | 0.74 | LSS (0.66) | LSSKMT2AMEN1 | |
| SCHEMBL7687517 | 0.74 | LSS (0.66) | LSSKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0636367-B1 | Use of phenylalkylamines for producing cholesterol lowering agents | HOFFMANN LA ROCHE (CH) | 2000-03-29 | — | — | EP | claimed |
| US-20100092479-A1 | Compositions and methods for treatment of viral diseases | COMBINATORX (SINGAPORE) PTE. LTD. (SG) | 2010-04-15 | — | — | US | disclosed |
| WO-2010021681-A2 | COMPOSITIONS AND METHODS FOR TREATMENT OF VIRAL DISEASES | COMBINATORX (SINGAPORE) PTE. LTD. (SG) | 2010-02-25 | — | — | WO | disclosed |
| US-5637771-A | Compound useful for lowering cholesterol | HOFFMANN-LA ROCHE INC. (US) | 1997-06-10 | — | — | US | disclosed |
| US-5574071-A | ADMINISTERING PHENYLALKYLAMINO KETONES | HOFFMANN-LA ROCHE INC. (US) | 1996-11-12 | — | — | US | disclosed |
| US-5495048-A | ANTICHOLESTEROL AGENTS | HOFFMANN-LA ROCHE INC. (US) | 1996-02-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100092479-A1 | Compositions and methods for treatment of viral diseases | HAVCR2, RNASE1, EIF2AK2 | LSS 2247/4885KMT2A 1512/4885MEN1 4176/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.